SCHEMBL5134064

SCHEMBL5134064

O=C1C(NS(=O)(=O)c2ccccc2)Cc2ccccc2N1Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPY1R P25929 2/20 0.54
XIAP P98170 3/20 0.46
POLB P06746 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
ADORA2A P29274 1/20 0.41
PYGL P06737 1/20 0.41
PAX8 Q06710 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5652840 0.92 NPY1R (0.54) NPY1RXIAPSMN1; SMN2MEN1KMT2A
SCHEMBL649728 0.87 ALDH1A1 (0.48) NPY1RXIAPPOLBSMN1; SMN2MEN1
SCHEMBL5133148 0.87 NPY1R (0.47) NPY1RXIAPPOLBSMN1; SMN2MEN1
SCHEMBL4802349 0.87 NPY1R (0.45) NPY1RXIAPPOLBSMN1; SMN2MEN1
SCHEMBL649727 0.87 ALDH1A1 (0.48) NPY1RXIAPPOLBSMN1; SMN2MEN1
SCHEMBL5655084 0.87 NPY1R (0.47) NPY1RXIAPPOLBSMN1; SMN2MEN1
SCHEMBL5132775 0.87 ALDH1A1 (0.48) NPY1RXIAPPOLBSMN1; SMN2MEN1
SCHEMBL10183595 0.87 NPY1R (0.47) NPY1RXIAPPOLBSMN1; SMN2MEN1
SCHEMBL5651200 0.84 FNTA (0.49) NPY1RXIAPSMN1; SMN2MEN1KMT2A
SCHEMBL5651206 0.84 FNTA (0.49) NPY1RXIAPSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1644370-A4 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2008-06-04 EP disclosed
US-7276608-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-02 US disclosed
US-7276608-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-02 US disclosed
US-7276608-B2 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-02 US disclosed
EP-1644370-A2 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS Bristol-Myers Squibb Company (US) 2006-04-12 EP disclosed
WO-2005007111-A2 TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-01-27 WO disclosed
US-20050009870-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009870-A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators CNR2, CNR1, OPRL1 NPY1R 326/4885XIAP 4524/4885POLB 4330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.